Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC) found ...

Panelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Prostate-specific membrane antigen (PSMA) expression in renal cell carcinoma (RCC) was an incidental finding but shows potential. Uncertainty regarding frequency of PSMA expression across RCC subtypes ...

Paul E. Dato, MD, discusses how the absence of genetic alterations in the second case makes the patient ineligible for PARP inhibitor therapy until castration resistance develops, with focus remaining ...

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency. Dr Shore provided guidance ...

At a median follow-up of 61.4 months, enzalutamide plus ADT continued to show an improvement in OS vs ADT alone. Initial results from the phase 3 ARCHES trial (NCT02677896) showed an overall survival ...

Future Directions for Imaging in Kidney Cancer Main Discussion Topics: Potential for deep learning and artificial intelligence (AI) to extract additional information from imaging data sets Recognition ...

EV+P showed a higher complete response rate and longer duration of response than chemotherapy in urothelial carcinoma patients. The median overall survival and progression-free survival were ...

Jim C. Hu, MD, MPH, shares in-depth findings comparing urinary continence recovery across 3 RARP approaches. Pelvic fascia-sparing techniques (Retzius-sparing, Hood) during robotic-assisted radical ...

The test demonstrated comparable or superior performance in Black and Non-White men. IsoPSA demonstrated comparable or superior diagnostic performance in Black and non-White men, underscoring its ...